153 related articles for article (PubMed ID: 37706178)
1. Novel
Yan L; Zheng J; Pan Q; Liang Y; Yu P; Chen Q
Front Oncol; 2023; 13():1264820. PubMed ID: 37706178
[TBL] [Abstract][Full Text] [Related]
2. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
3. Case report: Novel
Xue F; Xu S; Jiang C; Kang M; Usman M; Zhu L
Front Oncol; 2022; 12():1019624. PubMed ID: 36267987
[TBL] [Abstract][Full Text] [Related]
4. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
5. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
[TBL] [Abstract][Full Text] [Related]
6. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
7. Case report: Two novel
Liao S; Sun H; Wu J; Lu H; Fang Y; Wang Y; Liao W
Front Oncol; 2022; 12():916315. PubMed ID: 35941871
[TBL] [Abstract][Full Text] [Related]
8. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.
Gu X; Wang W; Wu W; Zhang Y; Shao L; Santarpia M; Christopoulos P; Myall NJ; Shi Z; Lou G
Transl Lung Cancer Res; 2022 May; 11(5):902-909. PubMed ID: 35693284
[TBL] [Abstract][Full Text] [Related]
9. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract][Full Text] [Related]
11.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
12. Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.
Li P; Ju X; Yang G
Discov Oncol; 2024 Feb; 15(1):43. PubMed ID: 38379102
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
[TBL] [Abstract][Full Text] [Related]
15. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
16. Classical
Zhai X; Liu Y; Liang Z; Wang W; Qin T; Liu SV; Um SW; Luo F; Liu J
Ann Transl Med; 2022 Nov; 10(21):1180. PubMed ID: 36467355
[TBL] [Abstract][Full Text] [Related]
17. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
Front Oncol; 2021; 11():700341. PubMed ID: 34490099
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.
Zhu L; Qin J
Discov Oncol; 2023 Apr; 14(1):44. PubMed ID: 37055606
[TBL] [Abstract][Full Text] [Related]
19. A Novel
Jia X; He Q; Xing X; Yang Y; Ma Y
Onco Targets Ther; 2022; 15():251-254. PubMed ID: 35313528
[TBL] [Abstract][Full Text] [Related]
20.
Sun N; Zhuang Y; Zhang J; Chen S; Dai Y; Guo R
Onco Targets Ther; 2021; 14():5161-5166. PubMed ID: 34729013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
